Multicenter prospective cohort study of the incidence of adverse events associated with cosmetic dermatologic procedures: lasers, energy devices, and injectable neurotoxins and fillers
- PMID: 25372511
- DOI: 10.1001/jamadermatol.2014.2494
Multicenter prospective cohort study of the incidence of adverse events associated with cosmetic dermatologic procedures: lasers, energy devices, and injectable neurotoxins and fillers
Erratum in
-
Error in table.JAMA Dermatol. 2015 Feb;151(2):236. doi: 10.1001/jamadermatol.2014.5173. JAMA Dermatol. 2015. PMID: 25671725 No abstract available.
Abstract
Importance: Common noninvasive to minimally invasive cosmetic dermatologic procedures are widely believed to be safe given the low incidence of reported adverse events, but reliable incidence data regarding adverse event rates are unavailable to date.
Objective: To assess the incidence of adverse events associated with noninvasive to minimally invasive cosmetic dermatologic procedures, including those involving laser and energy devices, as well as injectable neurotoxins and fillers.
Design, setting, and participants: A multicenter prospective cohort study (March 28, 2011, to December 30, 2011) of procedures performed using laser and energy devices, as well as injectable neurotoxins and soft-tissue augmentation materials, among 8 geographically dispersed US private and institutional dermatology outpatient clinical practices focused on cosmetic dermatology, with a total of 23 dermatologists. Participants represented a consecutive sample of 20 399 cosmetic procedures. Data acquisition was for 3 months (13 weeks) per center, with staggered start dates to account for seasonal variation.
Exposures: Web-based data collection daily at each center to record relevant procedures, by category type and subtype. Adverse events were detected by (1) initial observation by participating physicians or staff; (2) active ascertainment from patients, who were encouraged to self-report after their procedure; and (3) follow-up postprocedural phone calls to patients by staff, if appropriate. When adverse events were not observed by physicians but were suspected, follow-up visits were scheduled within 24 hours to characterize these events. Detailed information regarding each adverse event was entered into an online form.
Main outcomes and measures: The main outcome was the total incidence of procedure-related adverse events (total adverse events divided by total procedures performed), as verified by clinical examination.
Results: Forty-eight adverse events were reported, for a rate of 0.24% (95% CI, 0.18%-0.31%). Overall, 36 procedures resulted in at least 1 adverse event, for a rate of 0.18% (95% CI, 0.13%-0.25%). No serious adverse events were reported. Adverse events were infrequently associated with known risk factors.
Conclusions and relevance: Noninvasive to minimally invasive cosmetic dermatologic procedures, including energy, neurotoxin, and filler procedures, are safe when performed by experienced board-certified dermatologists. Adverse events occur in less than 1% of patients, and most of these are minor and transient.
Similar articles
-
Injectable neurotoxins and fillers: there is no free lunch.Clin Dermatol. 2011 Nov-Dec;29(6):678-90. doi: 10.1016/j.clindermatol.2011.08.005. Clin Dermatol. 2011. PMID: 22014990 Review.
-
Injection technique in neurotoxins and fillers: Planning and basic technique.J Am Acad Dermatol. 2018 Sep;79(3):407-419. doi: 10.1016/j.jaad.2018.01.034. J Am Acad Dermatol. 2018. PMID: 30119865 Review.
-
Rates of Vascular Occlusion Associated With Using Needles vs Cannulas for Filler Injection.JAMA Dermatol. 2021 Feb 1;157(2):174-180. doi: 10.1001/jamadermatol.2020.5102. JAMA Dermatol. 2021. PMID: 33377939 Free PMC article.
-
Determining the safety of office-based surgery: what 10 years of Florida data and 6 years of Alabama data reveal.Dermatol Surg. 2012 Feb;38(2):171-7. doi: 10.1111/j.1524-4725.2011.02206.x. Epub 2011 Oct 19. Dermatol Surg. 2012. PMID: 22093178
-
Complications of injectable fillers and neurotoxins.Dermatol Ther. 2011 Nov-Dec;24(6):524-36. doi: 10.1111/j.1529-8019.2012.01455.x. Dermatol Ther. 2011. PMID: 22515668 Review.
Cited by
-
The Hybrid Filler Technique: A 5-Year Retrospective Analysis.Aesthetic Plast Surg. 2024 Sep 26. doi: 10.1007/s00266-024-04387-2. Online ahead of print. Aesthetic Plast Surg. 2024. PMID: 39327280
-
Botulinum Toxin Type A and Hyaluronic Acid Dermal Fillers in Dentistry: A Systematic Review of Clinical Application and Indications.J Clin Med Res. 2024 Jun;16(6):273-283. doi: 10.14740/jocmr5202. Epub 2024 Jun 30. J Clin Med Res. 2024. PMID: 39027812 Free PMC article. Review.
-
Jawline Sharp Contouring With Hybrid Filler.Aesthetic Plast Surg. 2024 Jul 16. doi: 10.1007/s00266-024-04226-4. Online ahead of print. Aesthetic Plast Surg. 2024. PMID: 39014233
-
Complications After Botulinum Neurotoxin Type A and Dermal Filler Injections: Data From a Large Retrospective Cohort Study.Aesthet Surg J. 2023 Jan 9;43(1):NP56-NP63. doi: 10.1093/asj/sjac228. Aesthet Surg J. 2023. PMID: 35953448 Free PMC article. No abstract available.
-
In Vitro and Ex Vivo Investigation of Intralesional Sodium Thiosulfate as a Reversal Agent for Calcium Hydroxylapatite Soft Tissue Filler.J Invest Dermatol. 2022 Nov;142(11):3125-3127. doi: 10.1016/j.jid.2022.04.016. Epub 2022 May 5. J Invest Dermatol. 2022. PMID: 35526562 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
